2. Search Result
Search Result
Results for "

cyclic peptide inhibitors

" in MedChemExpress (MCE) Product Catalog:

74

Inhibitors & Agonists

1

Screening Libraries

58

Peptides

13

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10383
    SPSB2-iNOS inhibitory cyclic peptide-1

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .
    SPSB2-iNOS inhibitory cyclic peptide-1
  • HY-P11039
    IL-23 cyclic peptide inhibitor 281

    		Interleukin Related Inflammation/Immunology
    IL-23 cyclic peptide inhibitor 281, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 281 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .
    IL-23 cyclic peptide inhibitor 281
  • HY-P11038
    IL-23 cyclic peptide inhibitor 105

    		Interleukin Related Inflammation/Immunology
    IL-23 cyclic peptide inhibitor 105, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 105 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .
    IL-23 cyclic peptide inhibitor 105
  • HY-P11223
    CMF9

    		TGF-beta/Smad Inflammation/Immunology
    CMF9, a cyclic peptide molecule, is an inhibitor of the SMAD2-SMAD4 interaction. CMF9 effectively blocks the formation of the heterodimeric complex of SMAD2 and SMAD4 by inhibiting the phosphorylation of SMAD2. CMF9 has no effect on the phosphorylation of SMAD3 or SMAD1/5/8. CMF9 downregulates the expression of fibrotic markers α-SMA and COL1A1. CMF9 exhibits potent anti-fibrotic effects in mouse models by promoting the degradation of pathological extracellular matrix (ECM) and inhibiting inflammation. CMF9 can be used for the study of liver fibrosis .
    CMF9
  • HY-P11224
    RMI-L4

    		DNA/RNA Synthesis Cancer
    RMI-L4 is an efficient cyclic peptide inhibitor that can specifically disrupt the interaction between FANCM and RMI proteins with an IC50 of 54 nM. RMI-L4 engages the FANCM-binding pocket of RMI1/2 with nanomolar affinity (KD = 2.5 nM). RMI-L4 cannot penetrate the cell membrane and can be used to study the FANCM-RMI pathway targeting cancer with alternate lengthening of telomeres (ALT) .
    RMI-L4
  • HY-P10837
    LAG-3 cyclic peptide inhibitor 12

    		LAG-3 Inflammation/Immunology Cancer
    LAG-3 cyclic peptide inhibitor 12 (Cyclic peptide 12) is an inhibitor of LAG-3 with an IC50 value of 4.45 μM and a Ki value of 2.66 µM .
    LAG-3 cyclic peptide inhibitor 12
  • HY-P10835
    LAG-3 cyclic peptide inhibitor C25

    		LAG-3 Cancer
    LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 + T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
    LAG-3 cyclic peptide inhibitor C25
  • HY-P10383A
    SPSB2-iNOS inhibitory cyclic peptide-1 TFA

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .
    SPSB2-iNOS inhibitory cyclic peptide-1 TFA
  • HY-P10384A
    SPSB2-iNOS inhibitory cyclic peptide-2 TFA

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-2 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-2 (HY-P10384). SPSB2-iNOS inhibitory cyclic peptide-2 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 TFA is reduction-resistant and oxidatively stable .
    SPSB2-iNOS inhibitory cyclic peptide-2 TFA
  • HY-P10385A
    SPSB2-iNOS inhibitory cyclic peptide-3 TFA

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-3 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-3 (HY-P10385). SPSB2-iNOS inhibitory cyclic peptide-3 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 7 nM .
    SPSB2-iNOS inhibitory cyclic peptide-3 TFA
  • HY-P1789
    CTTHWGFTLC, CYCLIC

    		MMP Inflammation/Immunology Cancer
    CTTHWGFTLC, CYCLIC is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM .
    CTTHWGFTLC, CYCLIC
  • HY-P1789A
    CTTHWGFTLC, CYCLIC TFA

    		MMP Inflammation/Immunology Cancer
    CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM .
    CTTHWGFTLC, CYCLIC TFA
  • HY-P10384
    SPSB2-iNOS inhibitory cyclic peptide-2

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-2 (Compound CP2) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 is reduction-resistant and oxidatively stable .
    SPSB2-iNOS inhibitory cyclic peptide-2
  • HY-146127
    Grb2 SH2 domain inhibitor 1

    		EGFR Others
    Grb2 SH2 domain inhibitor 1 is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
    Grb2 SH2 domain inhibitor 1
  • HY-P11036
    p53-hDM2 cyclic peptide inhibitor 16e

    		MDM-2/p53 Cancer
    p53-hDM2 cyclic peptide inhibitor 16e is a p53-hDM2 cell-permeable peptide inhibitor with an IC50 of 9.24 nM for hDM2. p53-hDM2 cyclic peptide inhibitor 16e can be used for cancers like breast, colorectal and cervical cancers research .
    p53-hDM2 cyclic peptide inhibitor 16e
  • HY-146127A
    Grb2 SH2 domain inhibitor 1 TFA

    		Src Others
    Grb2 SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
    Grb2 SH2 domain inhibitor 1 TFA
  • HY-N14978
    Eurocidin D

    		Antibiotic Infection Inflammation/Immunology
    Eurocidin D is a cyclic peptide antibiotic. Eurocidin D can inhibit the degranulation of rat mast cells .
    Eurocidin D
  • HY-P1949
    Cyclic MKEY

    		CXCR Cardiovascular Disease Cancer
    Cyclic MKEY is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY also protects against stroke-induced brain injury in mice .
    Cyclic MKEY
  • HY-P1949A
    Cyclic MKEY TFA

    		CXCR Cardiovascular Disease Cancer
    Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice .
    Cyclic MKEY TFA
  • HY-134482
    PCSK9-IN-1

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-1 is a novel and highly potent cyclic peptide PCSK9 inhibitor with a Ki value of 1.46 nM.
    PCSK9-IN-1
  • HY-131083
    ε-Amanitin

    		DNA/RNA Synthesis ADC Payload Cancer
    ε-Amanitin, a cyclic peptide isolated from a variety of mushroom species, potently binds to and inhibits the activity of RNA polymerase II .
    ε-Amanitin
  • HY-P10051
    Cyclorasin 9A5

    		Ras Raf Cancer
    Cyclorasin 9A5 is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the Ras-Raf protein interaction with an IC50 of 120 nM .
    Cyclorasin 9A5
  • HY-P10051A
    Cyclorasin 9A5 TFA

    		Ras Raf Cancer
    Cyclorasin 9A5 TFA is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the Ras-Raf protein interaction with an IC50 of 120 nM .
    Cyclorasin 9A5 TFA
  • HY-113469A
    Cyclic GMP sodium
    1 Publications Verification

    		 Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP sodium
  • HY-113469
    Cyclic GMP
    1 Publications Verification

    		 Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP
  • HY-144752
    cSPM

    cyclic spermine

    		 Amyloid-β Neurological Disease
    cSPM (Cyclic spermine) is a Aβ42 inhibitor. cSPM could suppress the aggregation of three different peptides, Aβ42, amylin and insulin, and decreases cytotoxicity .
    cSPM
  • HY-W767865
    Cyclic GMP sodium-13C5

    		Isotope-Labeled Compounds Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP sodium- 13C5 is the 13C-labeled Cyclic GMP sodium (HY-113469A). Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP sodium-13C5
  • HY-113469AR
    Cyclic GMP sodium (Standard)

    		Reference Standards Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP sodium (Standard) is the analytical standard of Cyclic GMP sodium (HY-113469A). This product is intended for research and analytical applications. Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP sodium (Standard)
  • HY-113469R
    Cyclic GMP (Standard)

    		Endogenous Metabolite Reference Standards Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP (Standard) is the analytical standard of Cyclic GMP (HY-113469). This product is intended for research and analytical applications. Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP (Standard)
  • HY-W654000
    Cyclic GMP-13C,15N2

    Guanosine 3',5'-cyclic-13C,15N2 monophosphate

    		 Isotope-Labeled Compounds Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP- 13C, 15N2 is 13C and 15N labeled Cyclic GMP (HY-113469). Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP-13C,15N2
  • HY-P10385
    SPSB2-iNOS inhibitory cyclic peptide-3

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-3 (Compound CP3) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 7 nM .
    SPSB2-iNOS inhibitory cyclic peptide-3
  • HY-P1975
    Aureobasidin A
    2 Publications Verification

    Basifungin

    		 Antibiotic Fungal Parasite Infection Inflammation/Immunology
    Aureobasidin A (Basifungin) is a cyclic peptide antibiotic with oral activity. Aureobasidin A is an inhibitor of inositol phosphorylated ceramide synthetase AUR1. Aureobasidin A has antifungal and antiparasitic activity .
    Aureobasidin A
  • HY-113469B
    Cyclic GMP (TBAOH)
    1 Publications Verification

    		 Endogenous Metabolite Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP (cGMP) TBAOH, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP TBAOH occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP (TBAOH)
  • HY-P10033
    SFTI-1

    		Ser/Thr Protease Others
    SFTI-1 is a cyclic peptide trypsin inhibitor consisting of 14 amino acid residues. SFTI-1 belongs to the Bowman-Birk class of inhibitors. Characterized by its small size, high stability, and potent activity, SFTI-1 can be used for research on peptide drug design platforms .
    SFTI-1
  • HY-125053A
    Batifiban TFA

    		Glycoprotein VI Cardiovascular Disease
    Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .
    Batifiban TFA
  • HY-P1195
    PDZ1 Domain inhibitor peptide

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide
  • HY-P2206
    Zelkovamycin

    		Bacterial Antibiotic Infection
    Zelkovamycin is a cyclic peptide antibiotic originally isolated from Streptomyces. It inhibits growth of X. oryzae, P. oryzae, S. aureus, and A. laidlawii in a concentration-dependent manner when used at concentrations ranging from 0.01 to 300 μg/mL.
    Zelkovamycin
  • HY-P1195A
    PDZ1 Domain inhibitor peptide TFA

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide TFA
  • HY-149205
    CXJ-2

    		PI3K ERK Inflammation/Immunology
    CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy .
    CXJ-2
  • HY-P10860
    cMCoFx1

    		Factor Xa Cardiovascular Disease
    cMCoFx1 is a potent and selective FXIIa cyclic peptide inhibitor. cMCoFx1 has high binding affinity (KD: 900 pM) and inhibitory activity (Ki: 370 pM) for FXIIa. cMCoFx1 can effectively inhibit endogenous clotting pathways, and cMCoFx1 is stable in serum and non-cytotoxic .
    cMCoFx1
  • HY-125586
    β-Amanitin

    		DNA/RNA Synthesis ADC Payload Cancer
    β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
    β-Amanitin
  • HY-174986
    CGRP antagonist 7

    		CGRP Receptor Cardiovascular Disease
    CGRP antagonist 7 is a potent calcitonin gene-related peptide receptor (CGRP) antagonist with a Ki of 0.029 nM. CGRP antagonist 7 Inhibit the production of cyclic adenosine monophosphate (cAMP) with an IC50 of 1.5 nM. CGRP antagonist 7 can be used for the study of migraine .
    CGRP antagonist 7
  • HY-125053
    Batifiban

    		Integrin Cardiovascular Disease
    Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes .
    Batifiban
  • HY-P1420
    TAT-cyclo-CLLFVY
    2 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM .
    TAT-cyclo-CLLFVY
  • HY-W748000
    Kocurin

    PM181104; Baringolin

    		 Antibiotic Bacterial Infection
    Kocurin (PM181104) is a thiazolyl cyclic-peptide antibiotic. Kocurin inhibits bacterial growth by impeding bacterial protein biosynthesis during the translation phase. Kocurin has strong inhibitory activity against Gram-positive bacteria, but no activity against fungi and Gram-negative bacteria .
    Kocurin
  • HY-P1420A
    TAT-cyclo-CLLFVY TFA

    		HIF/HIF Prolyl-Hydroxylase Cancer
    TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY TFA disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM .
    TAT-cyclo-CLLFVY TFA
  • HY-P10858
    UCI-1

    		SARS-CoV Virus Protease Infection
    UCI-1 is a SARS-CoV-2 main protease (M pro) cyclic peptide inhibitor with an IC50 of 160 μM. UCI-1 shows no obvious cytotoxicity at the concentration of inhibiting M pro. UCI-1 can be used in the study of anti-COVID-19 drugs .
    UCI-1
  • HY-P2612A
    WP9QY TFA

    		TNF Receptor Others Cancer
    WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)
    WP9QY TFA
  • HY-P2612
    WP9QY

    		TNF Receptor Others
    WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)
    WP9QY
  • HY-P10135
    RES-701-1

    		Endothelin Receptor Cardiovascular Disease
    RES-701-1 is a cyclic peptide composed of 16 common L-amino acids, acting as a specific antagonist for the ETB receptor. RES-701-1 can inhibit the binding of 125I-ET-1 (125I-labeled Endothelin (ET)-1) to the ETB receptor, with an IC50 value of 10 nM .
    RES-701-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: